Generation of superoxide anion radicals and platelet glutathione peroxidase activity in patients with schizophrenia

Neuropsychiatric Disease and Treatment

Volumn 10, Issue , 2014, Pages 703-709

  Dietrich Muszalska, Anna ^a   Kwiatkowska, Anna ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Activating factors; Blood platelet; Glutathione peroxidase; Schizophrenia; Superoxide anion

Indexed keywords

GLUTATHIONE PEROXIDASE; SUPEROXIDE; THROMBOCYTE ACTIVATING FACTOR;

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE ASSOCIATION; ENZYME ACTIVITY; FEMALE; HUMAN; HUMAN CELL; MALE; OXIDATIVE STRESS; SCHIZOPHRENIA; THROMBOCYTE;

EID: 84899863029     PISSN: 11766328     EISSN: 11782021     Source Type: Journal    
DOI: 10.2147/NDT.S60034     Document Type: Article

References (52)

1. Ciobica A, Padurariu M, Dobrin I, Stefanescu C, Dobrin R. Oxidative stress in schizophrenia focusing on the main markers. Psychiatr Danub. 2011;23:237-245.
2. Dietrich-Muszalska A, Olas B, Rabe-Jabłońska J. Oxidative stress in blood platelets from schizophrenic patients. Platelets. 2005;16: 386-391.
3. Fendri C, Mechri A, Khiari G, Othman A, Kerkeni A, Gaha L. Oxidative stress involvement in schizophrenia pathophysiology: a review. Encephale. 2006;32:244-252. French.
4. Li HC, Chen QZ, Ma Y, Zhou JF. Imbalanced free radicals and antioxidant defense systems in schizophrenia: a comparative study. J Zhejiang Univ Sci B. 2006;7:981-986.
5. Micó JA, Rojas-Corrales MO, Gibert-Rahola J, et al. Reduced antioxidant defense in early onset first-episode psychosis: a case-control study. BMC Psychiatry. 2011;11:26.
6. Raffa M, Atig F, Mhalla A, Kerkeni A, Mechri A. Decreased glutathione levels and impaired antioxidant enzyme activities in drug-naïve firstepisode schizophrenic patients. BMC Psychiatry. 2011;11:124.
7. Reddy R, Yao JK. Free radical pathology in schizophrenia: a review. Prostaglandins Leukot Essent Fatty Acids. 1996;55:33-43.
8. Yao JK, Reddy R. Oxidative stress in schizophrenia: pathogenetic and therapeutic implications. Antioxid Redox Signal. 2011;15: 1999-2002.
9. Yao JK, Reddy R, McElhinny LG, van Kammen DP. Reduced status of plasma total antioxidant capacity in schizophrenia. Schizoph Res. 1998;32:1-8.
10. Yao JK, Reddy R, van Kammen DP. Oxidative damage and schizophrenia. CNS Drugs. 2001;15:287-210.
11. Berk M, Plein H, Belsham B. The specificity of platelet glutamate receptor supersensitivity in psychotic disorders. Life Sci. 2000;66: 2427-2432.
12. Camacho A, Dimsdale JE. Platelets and psychiatry: lessons learned from old and new studies. Psychosom Med. 2000;62:326-336.
13. Dreux C, Launay JM. Blood platelets: neuronal model in psychiatric disorders. Encephale. 1985;11:57-64. French.
14. Plein H, Berk M. The platelet as a peripheral marker in psychiatric illness. Hum Psychopharmacol. 2001;16:229-236.
15. Carotenuto M, Esposito M. Nutraceuticals safety and eff icacy in migraine without aura in a population of children affected by neurofibromatosis type I. Neurol Sci. 2013;34:1905-1909.
16. Esposito M, Ruberto M, Pascotto A, Carotenuto M. Nutraceutical preparations in childhood migraine prophylaxis: effects on headache outcomes including disability and behaviour. Neurol Sci. 2012;33: 1365-1368.
17. Iuliano L, Colavita AR, Leo R, Praticò D, Violi F. Oxygen free radicals and platelet activation. Free Radic Biol Med. 1997;22:999-1006.
18. Wachowicz B, Olas B, Zbikowska HM, Buczyński A. Generation of reactive oxygen species in blood platelets. Platelets. 2002;13: 175-182.
19. Olas B, Wachowicz B. Role of reactive nitrogen species in blood platelets functions. Platelets. 2007;18:555-565.
20. Olas B, Nowak P, Kolodziejczyk J, Wachowicz B. The effects of antioxidants on peroxynitrite-induced changes in platelet proteins. Thromb Res. 2004;113:399-406.
21. Do KQ, Trabesinger AH, Kirsten-Krüger M, et al. Schizophrenia: glutathione deficit in cerebrospinal fluid and prefrontal cortex in vivo. Eur J Neurosci. 2000;12:3721-3728.
22. Do KQ, Lauer CJ, Schreiber W, et al. γ-Glutamylglutamine and t{stroke}aurine concentrations are decreased in the cerebrospinal fluid of drugnaive patients with schizophrenic disorders. J Neurochem. 1995;65: 2652-2662.
23. Berk M, Ng F, Dean O, Dodd S, Bush AI. Glutathione: a novel treatment target in psychiatry. Trends Pharmacol Sci. 2008;29:346-351.
24. Dean O, Giorlando F, Berk M. N-acetylcysteine in psychiatry: current therapeutic evidence and potential mechanisms of action. Psychiatry Neurosci. 2011;36:78-86.
25. Sheehan DV, Lecrubier Y, Sheehan KH, et al. The Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry. 1998;59:22-33.
26. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 4th ed. Washington: American Psychiatric Press 1994.
27. Wachowicz B, Kustron J. Effect of cisplatin on lipid peroxidation in pig blood platelets. Cytobios. 1992;70:41-47.
28. Jahn B, Hänsch GM. Oxygen radical generation in human platelets: dependence on 12-lipoxygenase activity and on the glutathione cycle. Int Arch Allergy Appl Immunol. 1990;93:73-79.
29. Walkowiak B, Michalak E, Koziolkiewicz W, Cierniewski CS. Rapid photometric method for estimation of platelet count in blood plasma or platelet suspension. Thromb Res. 1989;56:763-776.
30. Paglia DE, Valentine WN. Studies on the quantitative and qualitative characterization of erythrocyte glutathione peroxidase. J Lab Clin Med. 1967;70:158-169.
31. Bradfort MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248-254.
32. Dietrich-Muszalska A, Olas B. The changes of aggregability of blood platelets in schizophrenia. World J Biol Psychiatry. 2009;10: 171-176.
33. Lapetina EG. The signal transduction induced by thrombin in human platelets. FEBS Lett. 1990;268:400-404.
34. Rípová D, Strunecká A, Platilová V, Höschl C. Phosphoinositide signalling system in platelets of schizophrenic patients and the effect of neuroleptic therapy. Prostaglandins Leukot Essent Fatty Acids. 1999;61:125-129.
35. Walsh MT, Ryan M, Hillmann A, et al. Elevated expression of integrin alpha(IIb), beta(IIIa) in drug-naïve, first-episode schizophrenic patients. Biol Psychiatry. 2002;52:874-879.
36. Allebeck P. Schizophrenia: a life-shortening illness. Schizophr Bull. 1989;15:81-89.
37. Allebeck P, Wistedt B. Mortality in schizophrenia. A ten-year follow-up based on the Stockholm Country inpatient register. Arch Gen Psychiatry. 1986;43:650-653.
38. Ruschena D, Mullen PE, Burgess P, et al. Sudden death in psychiatric patients. Br J Psychiatry. 1998;172:331-336.
39. Ross BM. Phospholipid and eicosanoid signaling disturbances in schizophrenia. Prostaglandins Leukot Essent Fatty Acids. 2003;69, 6:407-412.
40. Kuloglu M, Ustundag B, Atmaca M, Canatan H, Tezcan AE, Cinkilinc N. Lipid peroxidation and antioxidant enzyme levels in patients with schizophrenia and bipolar disorder. Cell Biochem Funct. 2002;20:171-117.
41. Mahadik SP, Mukherjee S. Free radical pathology and antioxidant defence in schizophrenia: a review. Schizoph Res. 1996;19:1-17.
42. Raffa M, Mechri A, Othman LB, Fendri C, Gaha L, Kerkeni A. Decreased glutathione levels and antioxidant enzyme activities in untreated and treated schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry. 2009;33:1178-1183.
43. Buckman TD, Kling A, Sutphin MS, Steinberg A, Eiduson S. Platelet glutathione peroxidase and monoamine oxidase activity in schizophrenics with CT scan abnormalities: relation to psychosocial variables. Psychiatry Res. 1990;31:1-14.
44. Nowak P, Olas B, Bald E, Głowacki R, Wachowicz B. Peroxynitriteinduced changes of thiol groups in human blood platelets. Platelets. 2003;14:375-379.
45. Berry T. A selenium transport protein model of a sub-type of schizophrenia. Med Hypotheses. 1994;43:409-414.
46. Dietrich-Muszalska A, Olas B. Modification of blood platelet proteins of patients with schizophrenia. Platelets. 2009;20:90-96.
47. Miljevic C, Nikolic M, Nikolic-Kokic A, et al. Lipid status, anti-oxidant enzyme defence and haemoglobin content in the blood of long-term clozapine-treated schizophrenic patients. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34:303-307.
48. Padurariu M, Ciobica A, Dobrin I, Stefanescu C. Evaluation of antioxidant enzymes activities and lipid peroxidation in schizophrenic patients treated with typical and atypical antipsychotics. Neurosci Lett. 2010;479:317-320.
49. Raffa M, Barhoumi S, Atig F, Fendri C, Kerkeni A, Mechri A. Reduced antioxidant defense systems in schizophrenia and bipolar I disorder. Prog Neuropsychopharmacol Biol Psychiatry. 2012;39:371-375.
50. Zhang M, Zhao Z, He L, Wan C. A meta-analysis of oxidative stress markers in schizophrenia. Sci China Life Sci. 2010;53: 112-124.
51. Dietrich-Muszalska A, Olas B. Isoprostanes as indicators of oxidative stress in schizophrenia. World J Biol Psychiatry. 2007;8:1-7.
52. Bartosz G. Peroxynitrite: mediator of the toxic action of nitric oxide. Acta Biochim Pol. 1996;43:645-659.